Ç

Partner search

Company: Agroaerospace, S.L. (Sanzar)
CIF: ESB88360565

Address: Parque Tecnológico Av. Gregorio Peces Barba, 1. 28919 Leganés Madrid, Spain.	Contact Marco Ruano Position: Chairman Telephone: +34670272900 Email: marco.ruano@sanzar-group.com

Short Company presentation

(R&D guidelines, international activities, etc.)

Agroaerospace, hereinafter identified by Sanzar, which is its trademark, is a privately held Spanish company founded in 2019, focusing on aerospace, healthcare, and agro-tech. Sanzar offers AI software products and services across the agri-tech, healthcare, and space sectors. We have experience in international programmes and are conducting a €2.5M financing round, alongside €2.3M in our investment and public-private funding over the last two years, with an anticipated turnover of €350,000 by 2025. We are present in Europe, South-America and North Africa.

DESCRIPTION OF ITS TECHNOLOGY AND CAPABILITIES IN R & D

(Products, technologies, applications, services, etc.)

The company's offer is as follows:

- **AGRI-TECH**: Sanzar markets software to reduce costs and increase productivity in the agricultural and insurance sectors. We use machine learning models to enhance crop sustainability and yield through digital mapping. We offer a web application, a mobile application, and an API, employing B2B, B2C, and SaaS business models.

- **SPACE**: We focus on developing and implementing satellite attitude control systems (ACS) that feature variable-speed control moment gyroscopes (VSCMGs). Our mission is to provide ACS solutions that not only exceed traditional performance limits but also deliver unprecedented improvements in manoeuvrability and significant reductions in weight and volume. These innovations are not just incremental improvements; they represent substantial advancements that can lead to millions of dollars in operational and launch cost savings for our clients.

- **HEALTH**: Development of a new robotic system for minimally invasive surgery in collaboration with IDIVAL, the Institute of Valladolid in Santander. The development of a knee prosthesis was conducted at the King Faisal Hospital Research Institute in Saudi Arabia.


PROPOSED COLLABORATIVE PROJECT IN R & D

(As much detail as possible, both in what it offers and what you want in a potential partner)

• **Technology offered to international partners:**

Multi-platform web with responsive design, Mobile Application, High-Resolution Satellite Imagery, and AI for Land Risk and Damage Analysis. Access to over 20 different constellations with a resolution of up to 30cm per pixel.

We provide high-definition digital maps with crop and risk assessments to reduce costs, enhance productivity, and reduce evaluation time.

https://ai-land.sanzar-group.com/wp-content/uploads/2024/12/sanzarfile3.mp4

• **Technology looking for an international partner:**

The technology that are looking for is related to the following areas:

- Engineering services for agriculture, livestock and forestry
- Studies, evaluations and expert reports
- Drone operators

• **Other specifications, requirements or comments:**

The participation of companies in the insurance sector that can add value to the project is also considered.

• **PROPOSED COLLABORATIVE PROJECT IN R & D:**

We are open to R&D projects in agriculture, space, and healthcare that utilize artificial intelligence. In the case of agriculture, we could focus on reducing the use of chemical fertilizers on crops.

General comments:

- By sending this information document authorizing its dissemination.

- A profile of the company must be attached: https://sanzar-group.com/es/sanzar/

Partner search

Company:	
CIF: B90448598	
Adress: Tecnoincubadora Marie Curie C. Leonardo da Vinci, 18 41092 - Sevilla	**Contact:** Estefanía Posadas **Position:** Administration **Telephone:** 676494279 **Email:** admin@dupontegroup.com

Short Company presentation

(R & D guidelines, international activities, etc.)

DUPONTE Investigación y Desarrollo S.L. is a Spanish company founded in 2019 and based in Seville, specializing in pharmacogenetics and personalized medicine. Its mission is to provide advanced solutions for individualized treatments by identifying genetic variants associated with drug response and disease predisposition. The company focuses on improving clinical decision-making, enhancing patient care through precision medicine.

The company directs its R&D efforts into two key areas: the use of **Artificial Intelligence** for the interpretation of complex genomic data and the development of personalized solutions based on the genetic profile of individuals. Through these advances, DUPONTE is leading groundbreaking research in pharmacogenetics, with notable projects focused on identifying genetic biomarkers for diseases like rheumatoid arthritis and the response to chemotherapy treatments.

Internationally, DUPONTE is actively involved in R&D+i projects, collaborating with institutions and professionals in the sector to push the boundaries of pharmacogenetics using advanced technologies such as next-generation sequencing. The company has also formed strategic partnerships with doctors, biologists, and pharmacists to tailor its developments to the needs of the healthcare sector and improve efficiency in patient diagnosis and treatment.

DESCRIPTION OF ITS TECHNOLOGY AND CAPABILITIES IN R & D

(Products, technologies, applications, services, etc.)

DUPONTE Investigación y Desarrollo S.L. stands out for its ability to integrate cutting-edge technology into its research and development projects. Its primary focus is the use of **Artificial Intelligence** for interpreting genomic data, enabling healthcare professionals to make faster and more accurate diagnoses, ultimately improving the effectiveness of personalized treatments.

In terms of **products and services**, DUPONTE has developed the **MATCHGÉNICA** platform, an award-winning tool that facilitates the interpretation of genetic data through semi-automated reports. This platform helps healthcare professionals make more informed clinical decisions by considering both the genetic variants of patients and the most suitable pharmaceutical treatments.

The company is also working on developing a **precision diagnostic kit** that combines artificial intelligence with the analysis of genetic variants associated with cancer and the response to current drug treatments, as well as clinical factors related to disease progression. This kit has the potential to revolutionize early diagnosis and the customization of treatments for cancer patients.

Regarding **technological applications**, DUPONTE focuses on the implementation of **next-generation sequencing technologies** to advance the understanding of pharmacogenetics. These technologies enable deep, detailed genomic analyses that facilitate the identification of key biomarkers for various diseases.

The company also offers **consulting and collaboration services** to other research institutions, laboratories, and healthcare professionals, enabling its technologies to be integrated into diverse working environments, from hospitals to research centers, contributing to the automation and optimization of genetic processes in clinical practice.

PROPOSED COLLABORATIVE PROJECT IN R & D

(As much detail as possible, both in what it offers and what you want in a potential partner)

• **Technology offered to international partners:**

DUPONTE Investigación y Desarrollo S.L. offers advanced genomic analysis platforms powered by Artificial Intelligence to facilitate the interpretation of complex genetic data. Specifically, the MATCHGÉNICA platform, which uses AI to generate semi-automated reports, enabling faster and more accurate clinical decision-making. The company also offers its expertise in next-generation sequencing (NGS) technologies for deep genomic analysis and biomarker discovery. These tools are ideal for improving the precision of medical treatments, particularly in pharmacogenetics and personalized medicine.

Additionally, DUPONTE offers its research expertise in identifying genetic biomarkers related to diseases such as rheumatoid arthritis and cancer, as well as its work on developing precision diagnostic kits that integrate genetic data with clinical factors for the diagnosis and treatment of cancer.

• **Technology looking for an international partner:**

DUPONTE seeks international partners who can contribute to the development and application of Artificial Intelligence in the interpretation of genomic data, particularly in the context of cancer diagnostics and personalized treatment protocols. We are interested in partnering with organizations that have expertise in the following areas:

AI-driven data interpretation and machine learning algorithms tailored to genetic data Next-generation sequencing technology for genomic research and clinical applications Development of advanced diagnostic kits combining genetic analysis and clinical factors, particularly in oncology
Collaborative efforts in validating genetic biomarkers and advancing pharmacogenetic applications in drug response research

• **Other specifications, requirements or comments:**

The ideal international partner would be an organization or institution with strong capabilities in biotechnology, pharmacogenetics, AI, and data analysis. We are particularly interested in partners who have experience working in precision medicine, clinical research, and genomic data interpretation. Our company values strong collaboration between research institutions, healthcare providers, and technology developers, and we are looking for partners who are committed to innovation and the successful translation of research findings into real-world clinical applications.

Moreover, we welcome partnerships with companies that offer access to clinical trial networks or have expertise in regulatory affairs to help expedite the process of bringing these innovative solutions to market.

• **PROPOSED COLLABORATIVE PROJECT IN R & D:**

DUPONTE proposes a collaborative research and development project focused on advancing

precision medicine and personalized treatment protocols using genomic data and AI-driven analysis. The primary objective is to develop an integrated diagnostic platform for personalized treatment of cancer patients. This platform will combine genetic markers, AI-powered analysis, and clinical data to provide tailored treatment recommendations, improving patient outcomes and reducing adverse drug reactions.

The collaborative project will involve joint research efforts to validate genetic biomarkers for cancer, develop algorithms for more accurate interpretation of genomic data, and refine the application of next-generation sequencing technologies. The partnership will also include the development of a user-friendly, scalable diagnostic kit that healthcare providers can easily incorporate into clinical practice for early cancer detection and personalized treatment planning.

DUPONTE envisions working with an international partner who can contribute expertise in clinical research, AI algorithm development, and regulatory aspects to accelerate the development and market introduction of this innovative solution. By combining the strengths of both organizations, we aim to create a groundbreaking tool for genomic-based precision oncology and extend its applications to other areas of personalized medicine.

General comments:

- By sending this information document authorizing its dissemination.
- A profile of the company must be attached: www.dupontegroup.com

Partner search

Company: Changetheblock	
CIF:	

Adress:	**Contact: Alan Draguilow**
Calle Albasanz 12. Oficina 1, 1º izq centro. Madrid, 28037	**Position: CEO**
	Telephone:
	Email: alan@changetheblock.com

Short Company presentation

(R & D guidelines, international activities, etc.)

ChangeTheBlock is a European technology company specialized in the development of AI-driven platforms for the healthcare sector. Our core expertise lies in interoperable data systems, predictive analytics, and advanced decision support tools for hospitals. With international experience in health data architectures and clinical AI, we collaborate with both private and public health institutions to drive innovation and support evidence-based care models.

DESCRIPTION OF ITS TECHNOLOGY AND CAPABILITIES IN R & D

(Products, technologies, applications, services, etc.)

IrisInsight is an R&D project led by ChangeTheBlock, focused on creating a clinical decision support platform powered by artificial intelligence. It uses deep learning and computer vision to analyze ophthalmological and radiological imaging (including retinal, iris, and CT scans) to detect early signs of diabetic retinopathy, cardiovascular conditions, and radiological anomalies.
The platform is designed to integrate with hospital information systems (HIS) and imaging archives (PACS), enhancing diagnostic accuracy and decision-making speed.

Built using explainable AI, IrisInsight complies with EU data protection and interoperability standards.

PROPOSED COLLABORATIVE PROJECT IN R & D

(As much detail as possible, both in what it offers and what you want in a potential partner)

- **Technology offered to international partners:** We are actively seeking **healthcare institutions in Brazil**—particularly **hospitals, diagnostic centers, or clinical research units**—interested in participating in collaborative **research and development** projects. The ideal partner would contribute with real-world clinical environments to **test and co-develop** functionalities, provide feedback on usability and impact, and help localize the platform to Brazilian healthcare workflows and regulatory requirements.

- **Technology looking for an international partner:** Beyond the clinical testing of the platform, we aim to engage in **joint R&D activities**, including participation in **publicly funded cooperation projects**. We are especially interested in partners open to innovation and long-term collaboration, with the capacity to influence clinical practices and participate in studies that measure AI's impact on diagnosis, workflows, and outcomes.

- **Other specifications, requirements or comments:** Beyond the clinical testing of the platform, we aim to engage in **joint R&D activities**, including participation in **publicly funded cooperation projects**. We are especially interested in partners open to innovation and long-term collaboration, with the capacity to influence clinical practices and participate in studies that measure AI's impact on diagnosis, workflows, and outcomes.

- **PROPOSED COLLABORATIVE PROJECT IN R & D:**

> We propose to adapt, validate, and expand the capabilities of IrisInsight in the Brazilian healthcare context. This includes co-developing new diagnostic modules, integrating with national health data standards, and demonstrating value in clinical and operational terms. The goal is to jointly deliver a version of IrisInsight ready for adoption in Brazil and scalable across Latin America.

General comments:

- By sending this information document authorizing its dissemination.
- A profile of the company must be attached